

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 April 2023 (27.04.2023)



(10) International Publication Number
WO 2023/069948 A1

(51) International Patent Classification:

C12N 15/11 (2006.01) C12N 15/81 (2006.01)
C12P 19/34 (2006.01)

(21) International Application Number:

PCT/US2022/078301

(22) International Filing Date:

18 October 2022 (18.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/262,690	18 October 2021 (18.10.2021)	US
63/304,913	31 January 2022 (31.01.2022)	US
63/373,293	23 August 2022 (23.08.2022)	US
63/402,772	31 August 2022 (31.08.2022)	US

(71) Applicant: **FLAGSHIP PIONEERING INNOVATIONS VII, LLC** [US/US]; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **SNEIDER, Alexandra Rachael**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **RUBENS, Jacob Rosenblum**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **PUJAR, Narahari Subbanna**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **GIBSON, Molly Krisann**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **PORTNEY, Benjamin Andrew**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **VON MALTZAHN, Geoffrey A.**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **BRETON, Camilo Ayala**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US).

(74) Agent: **KOYFMAN, Hannah** et al.; K&L Gates LLP, One Lincoln Street, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: DNA COMPOSITIONS AND RELATED METHODS

(57) Abstract: The disclosure provides, for example, single stranded, covalently closed DNA that does not form a double stranded structure longer than 100 base pairs. The ssDNA may encode an effector sequence, for instance a therapeutic protein. The ssDNA may comprise a nuclear targeting sequence (NTS). In some embodiments, the ssDNA shows decreased activation of the innate immune system compared to an otherwise similar dsDNA.

WO 2023/069948 A1